Biotech Startups

Twig.bio uses AI and machine learning to generate and score novel microbe designs — covering pathway and enzyme selection, gene edits, and expression levels — through its "dry lab" platform bio:drive, then transfers lab-ready designs to an automated system for growth. The company applies computational tools to accelerate microbial strain design and engineering for biotech applications.

4 investors

TwoStep Therapeutics is a Stanford spinout developing targeted cancer therapies, including peptide-based drug conjugates and radioligand programs built on a tumor-targeting peptide platform. The company is advancing a preclinical pipeline toward a first clinical trial planned for the second half of 2026.

4 investors

Ukko develops immuno-therapeutics for life-threatening food allergies using a computational protein design platform. It applies AI and protein micro-engineering to create modified allergens that retrain the immune system to tolerate the allergen without triggering an allergic response.

4 investors

Ultima Genomics develops genomic sequencing technology to scale omics information for advances in biology and human health improvements.

4 investors

Valo Health applies technology and data to drug discovery, working across the technology, biotech, and healthcare fields. It positions itself as a company focused on reshaping how new drugs are discovered.

4 investors

Variant Bio is a therapeutics company that uses human genomics to guide drug development, drawing on expertise across genetics, molecular biology, therapeutics, anthropology, and ethics.

4 investors

Vedanta Biosciences is a clinical-stage biotech developing Live Biotherapeutic Products (LBP) based on defined consortia of bacteria to treat serious gastrointestinal diseases, with an initial focus on preventing recurrent Clostridium difficile infection. Its oral therapies target gut dysbiosis-driven conditions.

4 investors

Velorium develops transformational medicines by combining scientific research with patient-focused collaboration. The company operates in the medical research and therapeutic development space.

4 investors

A biopharmaceutical company developing medicines and vaccines with a focus on clinical research and development for human health.

4 investors

Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men. The therapy is being evaluated in Phase 2 and Phase 3 clinical trials.

4 investors

Verisian builds software for clinical research and public health authorities to analyze and monitor clinical trial data in real-time, improving decision-making and trial safety. The platform addresses limitations in traditional CDISC standardization by streamlining analysis and submission cycles.

4 investors

4 investors

Viage Therapeutics is a neuroscience drug developer working on novel oral neurotherapeutics that target the gut-brain axis, including its lead clinical candidate DGX-001 for cognitive impairment in conditions such as Alzheimer's and Parkinson's disease. Its pipeline includes neuropeptides and small molecules aimed at cognitive impairment, depression, anxiety, and inflammatory disease.

4 investors

Vico Therapeutics is a genetic medicine company developing antisense oligonucleotide (ASO) therapies that target the CAG repeat expansion mutation underlying polyglutamine diseases such as Huntington's disease and spinocerebellar ataxias. Its lead clinical candidate, VO659, uses an allele-preferential approach to reduce disease-causing mutations while preserving normal gene function.

4 investors

Vima Therapeutics is a biotech company developing drug treatments for movement disorders such as dystonia and related neurological diseases. It is run by a team of physicians, scientists, and drug-development specialists focused on neurological conditions.

4 investors

VitaDAO is a decentralized autonomous organization that funds and coordinates longevity and aging research using AI agents, decentralized governance, and on-chain funding mechanisms such as IP-NFTs. It backs early-stage research projects and companies working on drug discovery and interventions to extend human healthspan and lifespan.

4 investors

Vitara Biomedical develops medical technology for the care of extremely premature newborns. The company is rooted in neonatology research from Children's Hospital of Philadelphia.

4 investors

Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.

4 investors

Volumetric Biotechnologies, acquired by 3D Systems in 2021, develops bioprinting materials and vascularized human tissue constructs. The company operates a bioprinting facility in Houston, Texas focused on advancing technologies for tissue engineering and bioprinted constructs.

4 investors

Wenzel Spine is a medical technology company that develops and manufactures products for minimally invasive spine surgery, including stand-alone spine fusion devices. It serves surgeons and their patients across the healthcare system, operating in the spine/orthopaedics medical device industry.

4 investors

Wheeler Bio operates as a contract development and manufacturing organization (CDMO) for biomanufacturing, providing development and manufacturing expertise for biologics therapeutics.

4 investors

Windgap Medical designs autoinjector devices for delivering complex drugs and combination products, including systems for reconstituting lyophilized or powdered compounds, sequential delivery of two liquid therapies, high-viscosity medications, and large-volume injections. It serves biopharmaceutical companies developing drug-device combination products.

4 investors

Allotera (formerly Wugen) develops allogeneic T-cell therapies. The company focuses on cell and gene therapy approaches for treating disease.

4 investors

X-Therma develops a proprietary peptoid-based technology that inhibits ice crystal formation to enable long-term sub-zero preservation and transport of cells, tissues, organs, and other biologics. Its products, including the XT-ViVo preservation solution and TimeSeal organ transport device, target organ and biologic preservation for transplantation.

4 investors